Research Papers:

Olmesartan attenuates pressure-overload- or post-infarction-induced cardiac remodeling in mice

Qiancheng Wang, Zhenhuan Chen, Xiaobo Huang, Lin Chen, Baihe Chen, Yingqi Zhu, Shiping Cao, Wangjun Liao, Jianping Bin, Masafumi Kitakaze and Yulin Liao _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:24601-24618. https://doi.org/10.18632/oncotarget.23628

Metrics: PDF 1541 views  |   HTML 2056 views  |   ?  


Qiancheng Wang1,2, Zhenhuan Chen1, Xiaobo Huang1, Lin Chen1, Baihe Chen1, Yingqi Zhu1, Shiping Cao1, Wangjun Liao3, Jianping Bin1, Masafumi Kitakaze1,4 and Yulin Liao1

1State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

2Department of Cardiology, Jiaozuo People's Hospital of Henan Province, Jiaozuo 454000, China

3Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

4Cardiovascular Division of the Department of Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka 565-8565, Japan

Correspondence to:

Yulin Liao, email: [email protected]

Xiaobo Huang, email: [email protected]

Keywords: periostin; olmesartan; myocardial hypertrophy; myocardial infarction; fibrosis

Received: April 07, 2017     Accepted: December 11, 2017     Epub: December 23, 2017     Published: May 15, 2018


Either angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor 1 blocker (ARB) attenuates cardiac remodeling. However, the overall molecular modulation of the reversing remodeling process in response to the ACEI or ARB treatment is not yet well determined. In this study, we examined whether gene expressions are modulated by ACEI (temocapril), ARB (olmesartan) or both in a murine model with transverse aortic constriction (TAC) and confirm whether periostin is a target gene of olmesartan in mice with myocardial infarction (MI). We detected 109 genes that were significantly up-regulated in TAC mice and a majority of these were down-regulated in response to temocapril, olmesartan or their combination which significantly attenuated cardiac remodeling at one or four weeks. Real-time RT-PCR demonstrated that olmesartan, temocapril or their combination down-regulated the expression of periostin. In MI mice treated with olmesartan for 4 weeks, the left ventricular end-diastolic and systolic dimensions measured with echocardiography were lower, whereas maximum rate of rise and fall rate of LV pressure (±dp/dt max) were greater, and Azan-staining cardiac fibrotic area was smaller. Furthermore, periostin was upregulated in response to MI, whereas olmesartan blocked this upregulation. Post-MI fibrosis was smaller in periostin knockout adult mice than in wildtype mice, while glycogen synthase kinase 3β was increased and cyclin D1 was decreased in periostin knockout mice. These findings indicate that periostin is a target gene of ARB and olmesartan reverses cardiac remodeling at least partially through the downregulation of periostin.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23628